Brandy Heckman-Stoddard, Ph.D., M.P.H.
Contracting Officer Representative
Breast and Gynecologic Cancer
Acting Chief | Community Oncology and Prevention Trials
Dr. Brandy Heckman-Stoddard received a Doctor of Philosophy degree in Molecular and Cellular Biology at Baylor College of Medicine focusing on the intersection of Rho and IGF signaling in mammary gland development and breast cancer before joining the National Cancer Institute as a Cancer Prevention Fellow in 2008. During the fellowship she completed a Master's in Public Health at the Johns Hopkins Bloomberg School of Public Health working with the Institute for Global Tobacco Control and the Evidence-Based Practice Center. During her time at NCI as a fellow, she focused on breast cancer prevention research including preclinical development and early clinical trials.
Dr. Heckman-Stoddard's research focuses on drug development for breast cancer prevention and biomarker development. She is particularly interested in local delivery of agents, alternate dosing strategies, biomarkers of efficacy to reduce the number needed to treat and targeting of stem cells. She serves as Program Officer for the Early Phase Breast Cancer Prevention Clinical Trials grants portfolio and scientific lead of early phase breast cancer clinical trials within the NCI Cancer Prevention Clinical Trial Network (CP-CTNet). Dr. Heckman-Stoddard is the NCI lead for an NCI-NIDDK collaboration examining cancer incidence within the Diabetes Prevention Program Outcomes Study a randomized study of metformin, lifestyle intervention, versus placebo. She also serves as the Breast Cancer Project Scientist and Uterine Cancer Project Scientist of the Cancer Intervention and Surveillance Modeling Network (CISNET), a consortium of NCI-sponsored investigators who use simulation modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and their effects on population trending in incidence and mortality. Dr. Heckman-Stoddard has developed and serves as the scientific contact on multiple funding opportunities including the NCI Clinical and Translation R21, the NCI Cancer Prevention and Control Clinical Trials Grants Program, and the NCI Cancer Prevention and Control Planning Grant Program.
In 2016, Dr. Heckman-Stoddard became the Chief of the Breast and Gynecologic Cancer Research Group (BGCRG) expanding the work of the group through supporting and recruiting additional staff. BGCRG currently includes 1 Senior Scientific Officer, 2 Medical Officers, 5 Health Scientist Administrators, a Nurse Consultant, a Scientific Program Analyst, and a Cancer Prevention Fellow.